Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials

Overview of attention for article published in The Journal of Headache and Pain, August 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 6 X users

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 33 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials

Article in The Journal of Headache and Pain (March 2024)

Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence

Article in Saudi Pharmaceutical Journal (February 2024)

One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

Article in The Journal of Headache and Pain (November 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.